Thus, due to the intimate interplay between BCL2-like family members and bioactive sphingolipids in apoptotic regulation, drugs that target both ceramide metabolism and anti-apoptotic BCL2 proteins may be good candidates for synergistic cancer therapies. Here, BCL2 is linked to cancer.